Client Spotlight: Kephera Diagnostics

Client: Kephera Diagnostics Client: Kephera Diagnostics

About The Company

In the ever-evolving world of healthcare, innovative companies are constantly emerging with groundbreaking solutions to address the most pressing challenges faced by medical professionals and patients alike. Enter: Kephera Diagnostics, a pioneering company at the forefront of diagnostic technology. With their unwavering commitment to improving patient outcomes, Kephera Diagnostics is revolutionizing the way we approach healthcare.

At the core of Kephera Diagnostics’ mission is the development of accurate, reliable, and accessible diagnostic tools that aid in the early detection and monitoring of diseases. By leveraging advanced immunological and molecular techniques, the company is developing a diverse portfolio of diagnostic tests that cater to a wide range of medical conditions. These tests not only provide faster and more precise results but also offer insights that enable healthcare professionals to make informed treatment decisions.

One of the key areas of focus for Kephera Diagnostics is emerging and neglected infectious diseases. With the global pandemic highlighting the ongoing threat of newly emerging pathogens, the company has been at the forefront of developing innovative diagnostic methods to enable a faster public health response. Kephera Diagnostics is currently developing an ultra-rapid point-of-care testing platform that will enable assay developers to quickly transition new tests from the lab to scaled up manufacturing and delivery to the field, wherever needed.

In May 2023, Kephera Diagnostics received a $3 million Phase II SBIR grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases. The grant will be used to develop and clinically validate a point-of-care test for neurocysticercosis, a potentially fatal infection of the central nervous system caused by the tapeworm Taenia solium, which accounts for one third of the world’s epilepsy cases. The test aims to differentiate neurocysticercosis from other causes of seizures in patients with epileptic-like symptoms. “[The grant] confirms the validity of our methodology and approach and will enable us to advance the test through clinical trials and to make it available commercially, where we believe it will fill an important gap in the diagnosis and treatment of patients presenting with seizures worldwide,” said Kephera Diagnostics CEO Andrew Levin in a recent statement.

Wolf Greenfield & Kephera Diagnostics

Wolf Greenfield has worked with Kephera to provide strategic intellectual property advice aimed at protecting Kephera’s innovations and positioning them for an advantageous position in the marketplace. Wolf Greenfield is also proud to have drafted and filed the first patent applications in Kephera’s name.

Straight From The Team

Developing a solid intellectual property position in the highly competitive field in which we work is critical to growing our business and building value for all stakeholders. Wolf Greenfield has the depth of scientific and technical expertise in diagnostics and medical device technologies that we rely on to build out our patent portfolio, navigate the IP challenges, and position Kephera for further development. Their ability to quickly assess patentability and turn ideas into patent applications has been of great value in support of our series of NIH SBIR-funded projects. We look forward to continuing our highly productive relationship with them.

Andrew Levin, PhD
Chief Executive Officer, Kephera Diagnostics, LLC

I’m very excited to see what the future holds for Kephera. They are becoming a trailblazer in the world of diagnostic technology, with a real focus on providing testing methodology and devices that overcome the shortfalls of existing options by improving precision, accuracy, and deployability. I have been particularly impressed with the potential impact their technology could have in remote testing locations, as patients in those areas stand to benefit most from improved diagnostics for infectious and other diseases. I’m grateful to be by their side as they continue this important work and grow their IP portfolio

Jonathan B. Roses
Shareholder, Pharmaceutical Practice, Wolf Greenfield